An update on heart disease risk associated with testosterone boosting medications

References

• Ibanez B, James S, Agewall S, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with st-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2017;2018(39):119–177.
   Google Scholar
• Towfighi A, Zheng L, Ovbiagele B. Sex-specific trends in midlife coronary heart disease risk and prevalence. Arch Intern Med. 2009;169:1762–1766.
   PubMedGoogle Scholar
• MMWR prevalence of coronary heart disease — United States. 2006–2010/October 14, 2011/Vol. 60/No. 40
   Google Scholar
• Bhatnagar P, Wickramasinghe K, Williams J, et al. The epidemiology of cardiovascular disease in the UK 2014. Heart. 2015;101:1182–1189.
   PubMed Web of Science ®Google Scholar
• Dixit KCS, Wu J, Smith LB, et al. Androgens and coronary artery disease. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc; 2000–2015 Jul 15.
   Google Scholar
• Corona G, Vignozzi L, Sforza A, et al. Risks and benefits of late onset hypogonadism treatment: an expert opinion. World J Mens Health. 2013;31:103–125.
   PubMedGoogle Scholar
• Corona G, Rastrelli G, Di Pasquale G, et al. Endogenous testosterone levels and cardiovascular risk: meta-analysis of observational studies. J Sex Med. 2018;15:1260–1271.
   PubMed Web of Science ®Google Scholar
• Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363:109–122.
   PubMed Web of Science ®Google Scholar
• Vigen R, O‘Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310:1829–1836.
   PubMed Web of Science ®Google Scholar
• Finkle WD, Greenland S, Ridgeway GK, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoSOne. 2014;9:e85805.
   PubMed Web of Science ®Google Scholar
• Santi D, Giannetta E, Isidori AM, et al. Therapy of endocrine disease. Effects of chronic use of phosphodiesterase inhibitors on endothelial markers in type 2 diabetes mellitus: a meta-analysis. Eur J Endocrinol. 2015;172:R103–14.
   PubMed Web of Science ®Google Scholar
• FDA Drug safety communication FDA cautions about using T products for low T due to aging requireslabeling change to inform of possible increased risk of heart attack and stroke with use. US Food and Drug Administration website; [updated 2015 Mar 3; cited 2019 Jan 11]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm436259.htmforHumanMedicalProducts/ucm402054.htm
   Google Scholar
• Layton JB, Kim Y, Alexander GC, et al. Association between direct-to-consumer advertising and testosterone testing and initiation in the United States, 2009-2013. JAMA. 2017;317:1159–1166.
   PubMed Web of Science ®Google Scholar
• Handelsman DJ. Global trends in testosterone prescribing, 2000-2011: expanding the spectrum of prescription drug misuse. Med J Aust. 2013;199:548–551.
   PubMed Web of Science ®Google Scholar
• Corona G, Maggi M. Deciding which testosterone therapy to prescribe. J Sex Med. 2018;15:619–621.
   PubMed Web of Science ®Google Scholar
• [cited 2019 Jan 11]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Testosterone-containing_medicines/human_referral_prac_000037.jsp&mid=WC0b01ac05805c516f
   Google Scholar
• Morden NE, Woloshin S, Brooks CG, et al. Trends in testosterone prescribing for age-related hypogonadism in men with and without heart disease. JAMA Intern Med. 2018 Dec;28. [Epub ahead of print]. DOI:10.1001/jamainternmed.2018.6505.
   Google Scholar
• Grossmann M, Matsumoto AM. A perspective on middle-aged and older men with functional hypogonadism: focus on holistic management. J Clin Endocrinol Metab. 2017;102:1067–1075.
   PubMed Web of Science ®Google Scholar
• Snyder PJ, Bhasin S, Cunningham GR, et al. Lessons from the testosterone trials. Endocr Rev. 2018;39:369–386.
   PubMed Web of Science ®Google Scholar
• Buvat J, Maggi M, Guay A, et al. Testosterone deficiency in men: systematic review and standard operating procedures for diagnosis and treatment. J Sex Med. 2013;10:245–284.
   PubMed Web of Science ®Google Scholar
• Corona G, Maggi M. Perspective: regulatory agencies‘ changes to testosterone product labeling. J Sex Med. 2015;12:1690–1693.
   PubMed Web of Science ®Google Scholar
• Corona G, Rastrelli G, Morgentaler A, et al. Meta-analysis of results of testosterone therapy on sexual function based on international index of erectile function scores. Eur Urol. 2017;72:1000–1011.
   PubMed Web of Science ®Google Scholar
• Corona G, Isidori AM, Buvat J, et al. Testosterone supplementation and sexual function: a meta-analysis study. J Sex Med. 2014;11:1577–1592.
   PubMed Web of Science ®Google Scholar
• Rastrelli G, Corona G, Maggi M. Testosterone and sexualfunction in men. Maturitas. 2018;112:46–52.
   PubMed Web of Science ®Google Scholar
• Corona G, Giagulli VA, Maseroli E, et al. Testosterone supplementation and body composition: results from a meta-analysis of observational studies. J Endocrinol Invest. 2016;39:967–981.
   PubMed Web of Science ®Google Scholar
• Corona G, Giagulli VA, Maseroli E, et al. THERAPY OF ENDOCRINE DISEASE: testosterone supplementation and body composition: results from a meta-analysis study. Eur J Endocrinol. 2016;174:R99–116.
   PubMed Web of Science ®Google Scholar
• Corona G, Maseroli E, Maggi M. Injectable testosterone undecanoate for the treatment of hypogonadism. Expert Opin Pharmacother. 2014;15:1903–1926.
   PubMed Web of Science ®Google Scholar
• Araujo AB, Dixon JM, Suarez EA, et al. Endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011;96:3007–3019.
   PubMed Web of Science ®Google Scholar
• Corona G, Rastrelli G, Monami M, et al. Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol. 2011;165:687–701.
   PubMed Web of Science ®Google Scholar
• Ruige JB, Mahmoud AM, De Bacquer D, et al. Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysis. Heart. 2011;97:870–875.
   PubMed Web of Science ®Google Scholar
• Rastrelli G, Guaraldi F, Reismann Y, et al. Testosterone replacement therapy for sexual symptoms.Sex Med Rev. 2019 Feb 22;S2050-0521(18)30131–8. doi: 10.1016/j.sxmr.2018.11.005.
   Google Scholar
• Corona G, Isidori AM, Aversa A, et al. Endocrinologic control of men‘s sexual desire and arousal/erection. J Sex Med. 2016;13:317–337.
   PubMed Web of Science ®Google Scholar
• Vlachopoulos CV, Terentes-Printzios DG, Ioakeimidis NK, et al. Prediction of cardiovascular events and all-cause mortality with erectile dysfunction: a systematic review and meta-analysis of cohort studies. Circ Cardiovasc Qual Outcomes. 2013;6:99–109.
   PubMed Web of Science ®Google Scholar
• Rastrelli G, Corona G, Lotti F, et al. Flaccid penile acceleration as a marker of cardiovascular risk in men without classical risk factors. J Sex Med. 2014;11:173–186.
   PubMed Web of Science ®Google Scholar
• Corona G, Rastrelli G, Monami M, et al. Frequency of sexual activity and cardiovascular risk in subjects with erectile dysfunction: cross-sectional and longitudinal analyses. Andrology. 2013;1:864–871.
   PubMed Web of Science ®Google Scholar
• Corona G, Rastrelli G, Filippi S, et al. Erectile dysfunction and central obesity: an Italian perspective. Asian J Androl. 2014;16:581–591.
   PubMed Web of Science ®Google Scholar
• Corona G, Monami M, Boddi V, et al. Low testosterone is associated with an increased risk of MACE lethality in subjects with erectile dysfunction. J Sex Med. 2010;7(4 Pt 1):1557–1564.
   PubMed Web of Science ®Google Scholar
• McGregor JC, Kim PW, Perencevich EN, et al. Utility of the chronic disease score and charlson comorbidity index as comorbidity measures for use in epidemiologic studies of antibiotic-resistant organisms. Am J Epidemiol. 2005;161:483–493.
   PubMed Web of Science ®Google Scholar
• Yeap BB, Alfonso H, Chubb SA, et al. In older men, higher plasma testosterone or dihydrotestosterone is an independent predictor for reduced incidence of stroke but not myocardial infarction. J Clin Endocrinol Metab. 2014;99:4565–4573.
   PubMed Web of Science ®Google Scholar
• Daka B, Langer RD, Larsson CA, et al. Low concentrations of serum testosterone predict acute myocardial infarction in men with type 2 diabetes mellitus. BMC Endocrnol Disord. 2015;15:35.
   PubMed Web of Science ®Google Scholar
• Hajjar RR, Kaiser FE, Morley JE. Outcomes of long-term testosterone replacement in older hypogonadal males a retrospective analysis. J Clin Endocrinol Metab. 1997;82:3793–3796.
   PubMed Web of Science ®Google Scholar
• Baillargeon J, Urban RJ, Kuo YF, et al. Risk of myocardial infarction in older men receiving testosterone therapy. Ann Pharmacother. 2014;48:1138–1144.
   PubMed Web of Science ®Google Scholar
• Finkle WD, Greenland S, Ridgeway GK, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One. 2014;9:e85805.
   PubMed Web of Science ®Google Scholar
• Etminan M, Skeldon SC, Goldenberg SL, et al. Testosterone therapy and risk of myocardial infarction a pharmaco-epidemiologic study. Pharmacotherapy. 2015;35:72–78.
   PubMed Web of Science ®Google Scholar
• Ramasamy R, Scovell J, Mederos M, et al. Association between testosterone supplementation therapy and thrombotic events in elderly men. Urology. 2015;86:283–285.
   PubMedGoogle Scholar
• Sharma R, Oni OA, Gupta K, et al. Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. Eur Heart J. 2015;36:2706–2715.
   PubMed Web of Science ®Google Scholar
• Tan RS, Cook KR, Reilly WG. Myocardial infarction and stroke risk in young healthy men treated with injectable testosterone. Int J Endocrinol. 2015;970:750.
   Google Scholar
• Maggi M, Wu FC, Jones TH, et al. RHYME investigators. Testosterone treatment is not associated with increased risk of adverse cardiovascular events results from the Registry of Hypogonadism in Men (RHYME). Int J Clin Pract. 2016;70:843–852.
   PubMed Web of Science ®Google Scholar
• Cheetham TC, An J, Jacobsen SJ, et al. Association of testosterone replacement with cardiovascular outcomes among men with androgen deficiency. JAMA Intern Med. 2017;177:491–499.
   PubMed Web of Science ®Google Scholar
• Traish AM, Haider A, Haider KS, et al. Long-term testosterone therapy improves cardiometabolic function and reduces risk of cardiovascular disease in men with hypogonadism. J Cardiovasc Pharmacol Ther. 2017;22:414–433.
   PubMed Web of Science ®Google Scholar
• Li H, Mitchell L, Zhang X, et al. Testosterone therapy and risk of acute myocardial infarction in hypogonadal men: an administrative health care claims study. J Sex Med. 2017;14:1307–1317.
   PubMed Web of Science ®Google Scholar
• Jaffe MD. Effect of testosterone cypionate on postexercise ST segment depression.Br. Heart J. 1977;39:1217–1222.
   Google Scholar
• Rosano GM, Leonardo F, Pagnotta P, et al. Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation. 1999;99:1666–1670.
   PubMed Web of Science ®Google Scholar
• Webb CM, Adamson DL, de Zeigler D, et al. Effect of acute testosterone on myocardial ischemia in men with coronary artery disease. Am J Cardiol. 1999;83:437–439.
   PubMed Web of Science ®Google Scholar
• English KM, Steeds RP, Jones TH, et al. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: A randomized, double-blind, placebo-controlled study. Circulation. 2000;102:1906–1911.
   PubMed Web of Science ®Google Scholar
• Thompson PD, Ahlberg AW, Moyna NM, et al. Effect of intravenous testosterone on myocardial ischemia in men with coronary artery disease. Am Heart J. 2002;143:249–256.
   PubMed Web of Science ®Google Scholar
• Malkin CJ, Pugh PJ, Morris PD, et al. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart. 2004;90:871–876.
   PubMed Web of Science ®Google Scholar
• Mathur A, Malkin C, Saeed B, et al. Long-term benefits of testosterone replacement therapy on angina threshold and atheroma in men. Eur J Endocrinol. 2009;161:443–449.
   PubMed Web of Science ®Google Scholar
• Cornoldi A, Caminiti G, Marazzi G, et al. Effects of chronic testosterone administration on myocardial ischemia, lipid metabolism and insulin resistance in elderly male diabetic patients with coronary artery disease. Int J Cardiol. 2010;142:50–55.
   PubMed Web of Science ®Google Scholar
• Pugh PJ, Jones RD, West JN, et al. Testosterone treatment for men with chronic heart failure. Heart. 2004;90:446–447.
   PubMed Web of Science ®Google Scholar
• Malkin CJ, Pugh PJ, West JN, et al. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J. 2006;27:57–64.
   PubMed Web of Science ®Google Scholar
• Caminiti G, Volterrani M, Iellamo F, et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol. 2009;54:919–927.
   PubMed Web of Science ®Google Scholar
• Stout M, Tew GA, Doll H, et al. Testosterone therapy during exercise rehabilitation in male patients with chronic heart failure who have low testosterone status: a double-blind randomized controlled feasibility study. Am Heart J. 2012;164:893–901.
   PubMed Web of Science ®Google Scholar
• Calof OM, Singh AB, Lee ML, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci. 2005;60:1451–1457.
   PubMed Web of Science ®Google Scholar
• Haddad RM, Kennedy CC, Caples SM, et al. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007;82:29–39.
   PubMed Web of Science ®Google Scholar
• Fernández-Balsells MM, Murad MH, Lane M, et al. Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95:2560–2575.
   PubMed Web of Science ®Google Scholar
• Corona G, Maseroli E, Rastrelli G, et al. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opin Drug Saf. 2014;13:1327–1351.
   PubMed Web of Science ®Google Scholar
• Alexander GC, Iyer G, Lucas E, et al. Cardiovascular risks of exogenous testosterone use among men: a systematic review and meta-analysis. Am J Med. 2017;130:293–305.
   PubMed Web of Science ®Google Scholar
• Elliott J, Kelly SE, Millar AC, et al. Testosterone therapy in hypogonadal men: a systematic review and network meta-analysis. BMJ Open. 2017;7:e015284.
   PubMed Web of Science ®Google Scholar
• Corona G, Rastrelli G, Di Pasquale G, et al. Testosterone and cardiovascular risk: meta-analysis of interventional studies. J Sex Med. 2018;15:820–838.
   PubMed Web of Science ®Google Scholar
• Corona G, Dicuio M, Rastrelli G, et al. Testosterone treatment and cardiovascular and venous thromboembolism risk: what is ‘new‘? J Investig Med. 2017;65:964–973.
   PubMed Web of Science ®Google Scholar
• Corona G, Maseroli E, Rastrelli G, et al. Is late-onset hypogonadotropic hypogonadism a specific age-dependent disease, or merely an epiphenomenon caused by accumulating disease-burden? Minerva Endocrinol. 2016;41:196–210.
   PubMed Web of Science ®Google Scholar
• Grossmann M. Hypogonadism and male obesity: focus on unresolved questions. Clin Endocrinol (Oxf). 2018;89:11–21.
   PubMed Web of Science ®Google Scholar
• Isidori AM, Balercia G, Calogero AE, et al. Outcomes of androgen replacement therapy in adult male hypogonadism: recommendations from the Italian society of endocrinology. J Endocrinol Invest. 2015;38:103–112.
   PubMed Web of Science ®Google Scholar
• Shores MM, Smith NL, Forsberg CW, et al. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab. 2012;97:2050–2058.
   PubMed Web of Science ®Google Scholar
• Muraleedharan V, Marsh H, Kapoor D, et al. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol. 2013;169:725–733.
   PubMed Web of Science ®Google Scholar
• Eisenberg ML, Li S, Herder D, et al. Testosterone therapy and mortality risk. Int J Impot Res. 2015;27:46–48.
   PubMed Web of Science ®Google Scholar
• Webb CM, McNeill JG, Hayward CS, et al. Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation. 1999;100:1690–1696.
   PubMed Web of Science ®Google Scholar
• Yu J, Akishita M, Eto M, et al. Androgen receptor-dependent activation of endothelial nitric oxide synthase in vascular endothelial cells: role of phosphatidylinositol 3-kinase/akt pathway. Endocrinology. 2010;151:1822–1828.
   PubMed Web of Science ®Google Scholar
• Scragg JL, Jones RD, Channer KS, et al. Testosterone is a potent inhibitor of L-type Ca(2+) channels. Biochem Biophys Res Commun. 2004;318:503–506.
   PubMed Web of Science ®Google Scholar
• Hall J, Jones RD, Jones TH, et al. Selective inhibition of L-type Ca2+ channels in A7r5 cells by physiological levels of testosterone. Endocrinology. 2006;147:2675–2680.
   PubMed Web of Science ®Google Scholar
• Scragg JL, Dallas ML, Peers C. Molecular requirements for L-type Ca2+ channel blockade by testosterone. Cell Calcium. 2007;42:11–15.
   PubMed Web of Science ®Google Scholar
• Kelly DM1, Jones TH. Testosterone: a vascular hormone in health and disease. J Endocrinol. 2013;217:R47–71.
   PubMed Web of Science ®Google Scholar
• Budoff MJ, Ellenberg SS, Lewis CE, et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA. 2017;317:708–716.
   PubMed Web of Science ®Google Scholar
• Toma M, McAlister FA, Coglianese EE, et al. Testosterone supplementation in heart failure: a meta-analysis. Circ Heart Fail. 2012;5:315–321.
   PubMed Web of Science ®Google Scholar
• Iellamo F, Rosano G, Volterrani M. Testosterone deficiency and exercise intolerance in heart failure: treatment implications. Curr Heart Fail Rep. 2010;7:59–65.
   PubMedGoogle Scholar
• Yeap BB, Page ST, Grossmann M. Testosterone treatment in older men: clinical implications and unresolved questions from the Testosterone Trials. Lancet Diabetes Endocrinol. 2018;6:659–672.
   PubMed Web of Science ®Google Scholar
• Webb C, Collins P. Role of testosterone in the treatment of cardiovascular disease. Eur Cardiol. 2017;12:83–87.
   PubMed Web of Science ®Google Scholar
• Corona G, Rastrelli G, Reisman Y, et al. The safety of available treatments of male hypogonadism in organic and functional hypogonadism. Expert Opin Drug Saf. 2018;17:277–292.
   PubMed Web of Science ®Google Scholar
• Xu L, Freeman G, Cowling BJ, et al. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med. 2013;11:108.
   PubMed Web of Science ®Google Scholar
• Borst SE, Shuster JJ, Zou B, et al. Cardiovascular risks and elevation of serum DHT vary by route of testosterone administration: a systematic review and meta-analysis. BMC Med. 2014;12:211.
   PubMed Web of Science ®Google Scholar
• Albert SG, Morley JE. Testosterone therapy, association with age, initiation and mode of therapy with cardiovascular events: a systematic review. Clin Endocrinol (Oxf). 2016;85:436–443.
   PubMed Web of Science ®Google Scholar